Why I'll Likely Sell Haleon Shares After GSK Demerger
seekingalpha.com
finance
2022-06-02 19:40:37

Scott Olson/Getty Images News GlaxoSmithKline (NYSE:GSK) is only one month away from their planned demerger with their Consumer Health business which will be listed under the name "Haleon". Shareholders still need to approve the transaction in June for the anticipated spin-off in July. At GSK's current valuation the estimated dividend yield (after the dividend cut post spin-off) is around 3% going forward. Â£50 Billion IPO I view Haleon (GSKs healthcare unit) as a defensive in nature due to their stable/predictable income and moderately growing dividend.
